{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-011960","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.958279+00:00","generated_at":"2026-05-24T23:53:00.785051+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lyell Q4 net loss $191.9M; cash $383.5M; IMPT-314 pivotal trials set for mid-2025, early 2026","bullets":["Net loss of $191.9M in Q4 2024 included $87.2M acquired IPR&D from ImmPACT Bio and $51.3M long-lived asset impairment.","Cash, equivalents and marketable securities of $383.5M at Dec 31, 2024; expected to fund operations into 2027.","IMPT-314 Phase 1/2 showed 94% ORR (16/17) and 71% complete response by 3 months; no Grade 3+ CRS in 23 patients.","Pivotal trial for IMPT-314 in 3rd line+ LBCL expected mid-2025; 2nd line pivotal expected by early 2026.","Non-GAAP net loss Q4 2024 was $45.9M vs $43.9M in Q4 2023; full year 2024 non-GAAP net loss $159.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-011960","json":"https://secwatch.observer/filing/0001628280-25-011960.json","markdown":"https://secwatch.observer/filing/0001628280-25-011960.md","text":"https://secwatch.observer/filing/0001628280-25-011960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828025011960/0001628280-25-011960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828025011960/lyel-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:53:00.785051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}